The company
BioVersys is a privately-held Swiss biopharmaceutical company with major focus on the research and development of New Chemical Entities (NCEs) targeting Transcriptional Regulators. By means of the company’s award-winning, proprietary TRIC technology, BioVersys has shown that it is possible: A) to shut off resistance to a given antibiotic in XDR pathogens and therefore restore antibiotic efficacy, B) to tune down virulence factors and/or biofilm formation and thus reduce risks of infection (prophylaxis) or “boost” efficacy of available antibiotics and C) to prevent transcription of essential genes.

By this, BioVersys addresses high medical needs for new treatment options against life-threatening bacterial infections. In most cases, BioVersys’ drug products will be used in combination with an existing antibiotic for instance to restore its efficacy against XDR pathogens; combination of an existing antibiotic with a TRIC-NCE represents an opportunity for rejuvenating IP of the “old” drug. The current research focuses on Nosocomial Infections (hospital infections) and Tuberculosis (TB). Against TB BioVersys is developing a TRIC candidate in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille.

TRIC Platform: Approach – Results
- The cartoon to the left exemplifies BioVersys’ approach to combat AntiMicrobial Resistance: Multiple endogenous and acquired resistance mechanisms (efflux pumps, degradation enzymes, target modification) may accumulate in pathogens to “resist” the antibiotic action. However, the expression of resistance has a metabolic cost for the bacterium and therefore expression is regulated at a transcriptional level. A TRIC molecule switches-off the antibiotic resistance mechanism at the transcriptional level thus restoring antibiotic activity.
- The graphic above provides a picture of BioVersys pipeline and projects a plausible development of the portfolio in a realistic time-frame.
- Two examples of the TRIC technology will be presented on Tuesday one in the morning and one in the afternoon in Hall C and B, respectively

Network
- Awards:
- Partners:
- Supporters:

Contact
Website: http://www.bioversys.com
Email: sergio.lociuro@bioversys.com